Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Next Generation Internet ETF (ARKW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

ARK Next Generation Internet ETFTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

ARK Next Generation Internet ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? ARK Next Generation Internet ETF trades at $148.16, while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, ARK Next Generation Internet ETF nearer its low. Which is the better fit depends on your goals.

ARKWVRTX
Sector
Sector/ThematicHealth
52-Week High
$182.20$529.65
52-Week Low
$114.45$376.62
Market Cap
$134.25B
Enterprise Value
$128.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Next Generation Internet ETF

ARKW trades at $147.92, up 3.11% today, with bullish technical signals from moving averages and a neutral oscillator stance. The ETF focuses on next-generation internet companies including AI and cloud infrastructure plays. Recent analysis highlights near-term headwinds from elevated capital spending but maintains long-term growth potential in agentic AI and physical AI technologies.

The ETF faces market skepticism around current AI infrastructure investments but offers exposure to innovative technology leaders. Key risks include sector concentration and volatility, while institutional interest remains strong in transformative technology themes driving long-term growth prospects.

Vertex Pharmaceuticals Incorporated

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About ARK Next Generation Internet ETF

ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.

Read more on ARKW

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX